Hajra Adrija, Ujjawal Aditi, Ghalib Natasha, Chowdhury Selia, Biswas Suman, Balasubramanian Prasanth, Gupta Rahul, Aronow Wilbert S
Brigham and Women's Hospital/Harvard Medical School, Boston, MA.
Saint Vincent Hospital, Worcester, MA.
Curr Probl Cardiol. 2024 Jan;49(1 Pt A):102017. doi: 10.1016/j.cpcardiol.2023.102017. Epub 2023 Aug 5.
Direct oral anticoagulants (DOAC) have emerged as a new therapy for patients who need and can tolerate oral anticoagulation. DOACs were initially approved for nonvalvular atrial fibrillation (NVAF) and treatment for deep vein thrombosis (DVT) and pulmonary embolism (PE). Ease of administration, no requirement of bridging with other anticoagulants, and less frequent dosing have made DOACs preferable choice for anticoagulation. Studies are showing promising results regarding use of DOACs beyond the common indications. Studies have been done to show the potential benefit of DOACs in valvular atrial fibrillation, heart failure, acute coronary syndrome, stroke, and peripheral arterial disease. Data have shown safety as well as comparable bleeding incidences with DOACs compared to vitamin K antagonist anticoagulants. Naturally interest is growing to see the use of DOACs apart from the NVAF, DVT, or PE. Authors have highlighted various study results to show the potential beneficial role of DOACs in the above-mentioned situations.
直接口服抗凝剂（DOAC）已成为有口服抗凝需求且能耐受的患者的一种新疗法。DOAC最初被批准用于非瓣膜性心房颤动（NVAF）以及治疗深静脉血栓形成（DVT）和肺栓塞（PE）。给药方便、无需与其他抗凝剂桥接以及给药频率较低，使得DOAC成为抗凝的首选。关于DOAC在常见适应症之外的使用，研究显示出了有前景的结果。已经开展的研究表明DOAC在瓣膜性心房颤动、心力衰竭、急性冠状动脉综合征、中风和外周动脉疾病中具有潜在益处。数据显示，与维生素K拮抗剂抗凝剂相比，DOAC具有安全性且出血发生率相当。自然而然，人们越来越关注DOAC在NVAF、DVT或PE之外的使用。作者强调了各种研究结果，以表明DOAC在上述情况中潜在的有益作用。
